Minerva Biotechnologies

Executive Summary

Minerva Biotechnologies is a private biotech company pioneering novel cancer immunotherapies and regenerative medicine technologies. The company's core discovery centers on the MUC1* growth factor receptor, a truncated form of MUC1 that is selectively expressed on many solid tumors and serves as a target for antibody-based therapies. Minerva's lead program, MBC-101 (a MUC1*-targeting antibody-drug conjugate), is in preclinical development for breast and ovarian cancers. Additionally, the company's stem cell platform leverages MUC1* to generate homogenous populations of stem cells, with potential applications in cell therapy and tissue repair. With over two decades of research, Minerva has built a strong intellectual property portfolio around MUC1*.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for MBC-10140% success
• Q3 2026Regulatory milestone or orphan drug designation for MUC1* program50% success
• TBDPartnership or licensing deal for stem cell platform45% success